Free Trial
NYSE:AMAM

Ambrx Biopharma (AMAM) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$28.00
$28.00
50-Day Range
$27.70
$28.00
52-Week Range
$6.55
$28.15
Volume
N/A
Average Volume
2.12 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.29

Ambrx Biopharma MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
16.8% Downside
$23.29 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.45) to ($1.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.10 out of 5 stars

Medical Sector

897th out of 901 stocks

Biological Products, Except Diagnostic Industry

151st out of 152 stocks

AMAM stock logo

About Ambrx Biopharma Stock (NYSE:AMAM)

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

AMAM Stock News Headlines

14 Day AMERIBOR Average Rate (^AMBRX)
Automatic Income (from home)
Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…
Johnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash Deal
3 Stocks to Buy That Are Up 200% or More in 2024
Automatic Income (from home)
Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…
Ambrx Biopharma just downgraded at JMP Securities, here's why
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
See More Headlines
Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
7/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.29
High Stock Price Target
$32.00
Low Stock Price Target
$9.00
Potential Upside/Downside
-16.8%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.40 million
Book Value
$3.05 per share

Miscellaneous

Free Float
62,746,000
Market Cap
$1.77 billion
Optionable
Optionable
Beta
-1.92
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Daniel J. O'Connor J.D. (Age 59)
    CEO, President & Director
    Comp: $509.94k
  • Ms. Sonja Nelson CPA (Age 51)
    Chief Financial Officer
    Comp: $1.18M
  • Mr. Andrew P. Aromando (Age 55)
    Chief Operating Officer
  • Dr. Ying J. Buechler Ph.D.
    Chief Technology Officer
  • Dr. Shawn Shao-Hui Zhang Ph.D.
    Chief Scientific Officer & GM of China
  • Mr. Jared Kelly
    Senior VP, General Counsel & Corporate Secretary
  • Mr. Robert Azzara
    Vice President of Human Capital
  • Dr. Sandra Aung Ph.D.
    Chief Clinical Officer
  • Ms. Renu Vaish M.Sc. (Age 57)
    Chief Regulatory Officer

AMAM Stock Analysis - Frequently Asked Questions

When did Ambrx Biopharma IPO?

Ambrx Biopharma (AMAM) raised $126 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.

This page (NYSE:AMAM) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners